CA3021571C - Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors - Google Patents

Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors Download PDF

Info

Publication number
CA3021571C
CA3021571C CA3021571A CA3021571A CA3021571C CA 3021571 C CA3021571 C CA 3021571C CA 3021571 A CA3021571 A CA 3021571A CA 3021571 A CA3021571 A CA 3021571A CA 3021571 C CA3021571 C CA 3021571C
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
alkyl
nad
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3021571A
Other languages
English (en)
French (fr)
Other versions
CA3021571A1 (en
Inventor
Ryan DELLINGER
Troy Rhonemus
Mark Morris
Aron Erickson
Hadi Cassier
Marie E. Migaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromadex Inc
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of CA3021571A1 publication Critical patent/CA3021571A1/en
Application granted granted Critical
Publication of CA3021571C publication Critical patent/CA3021571C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
CA3021571A 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors Active CA3021571C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325264P 2016-04-20 2016-04-20
US62/325,264 2016-04-20
PCT/US2017/028673 WO2017184885A1 (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors

Publications (2)

Publication Number Publication Date
CA3021571A1 CA3021571A1 (en) 2017-10-26
CA3021571C true CA3021571C (en) 2023-01-03

Family

ID=60088650

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3021571A Active CA3021571C (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors

Country Status (13)

Country Link
US (1) US10183036B2 (enExample)
EP (1) EP3445359B8 (enExample)
JP (3) JP7089480B2 (enExample)
KR (1) KR20190008246A (enExample)
CN (1) CN109640984A (enExample)
AU (2) AU2017254657A1 (enExample)
BR (1) BR112018071573A2 (enExample)
CA (1) CA3021571C (enExample)
ES (1) ES2948968T3 (enExample)
MX (1) MX393076B (enExample)
NZ (1) NZ747693A (enExample)
WO (1) WO2017184885A1 (enExample)
ZA (1) ZA201807736B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10392414B2 (en) 2015-07-15 2019-08-27 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
AU2016302005B2 (en) 2015-08-05 2021-03-04 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
EP3538099A4 (en) 2016-11-11 2020-06-17 The Queen's University of Belfast EFFICIENT AND SCALABLE SYNTHESIS OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS OF THEM, ADENYLYDINUCLEOTIDE CONJUGATES THEREOF AND NEW-WAY CRYSTALS
EP3554285A4 (en) 2016-11-29 2021-01-20 University of Iowa Research Foundation USE OF NAD PRECURSORS TO IMPROVE THE HEALTH OF MOTHER AND / OR OFFspring
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
WO2018191771A1 (en) * 2017-04-18 2018-10-25 Victor Chang Cardiac Research Institute Detection and treatment of congenital malformations
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
WO2019152416A1 (en) * 2018-01-30 2019-08-08 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CN113490675B (zh) * 2018-05-22 2026-01-09 江普斯塔特生育有限公司 作为抗衰老剂的烟酸核苷的氨基酸盐
US11833167B2 (en) 2018-12-17 2023-12-05 Mitopower Llc Nicotinyl riboside compounds and their uses
EP3927715A4 (en) * 2019-02-21 2023-03-01 Chromadex, Inc. Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
JP2022534872A (ja) * 2019-06-05 2022-08-04 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 肝疾患の治療のための還元型ニコチンアミドリボシド
AU2020286602B2 (en) * 2019-06-05 2025-04-03 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for treating or preventing kidney disease
BR112021021690A2 (pt) * 2019-06-05 2022-02-15 Nestle Sa Ribosídeos de nicotinamida reduzidos para tratamento/prevenção de doenças do músculo esquelético
CN110973260A (zh) * 2019-12-11 2020-04-10 杨力 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用
EP4076458A1 (en) 2019-12-19 2022-10-26 Leibniz-lnstitut Für Altersforschung Nad-precursors and dietary restriction for treating age-related medical conditions
EP4117681A1 (en) * 2020-03-09 2023-01-18 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions
WO2021180731A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions
US20230114280A1 (en) * 2020-03-09 2023-04-13 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions
EP4117680A1 (en) * 2020-03-09 2023-01-18 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of lung diseases and conditions
CN114561342B (zh) * 2020-11-27 2024-12-20 西安交通大学医学院第一附属医院 Nad信号通路激动剂在体外胚胎培养中的应用
CN112716969B (zh) * 2021-01-15 2022-11-29 江苏恒正合生命科学有限公司 治疗阿尔茨海默症的组合物及其制备方法、应用
CN118201621A (zh) * 2021-05-05 2024-06-14 雀巢产品有限公司 使用narh和nr的组合来产生细胞内烟酰胺腺嘌呤二核苷酸（nad+）的组合物和方法
IL308577A (en) 2021-05-27 2024-01-01 Metro Int Biotech Llc Crystalline solids of nicotinic acid mononucleotides and their esters and methods for their preparation and use
CA3224544A1 (en) * 2021-06-18 2022-12-22 Mitopower Llc Treatment of immune-related disorders, kidney disorders, liver disorders, hemolytic disorders, and oxidative stress-associated disorders using nrh, narh and reduced derivatives thereof
JP7111878B1 (ja) 2021-10-27 2022-08-02 旭化成ファーマ株式会社 ニコチンアミドモノヌクレオチドの製造方法
EP4422644A4 (en) * 2021-10-27 2025-08-27 Elysium Health Inc METHODS OF TREATING MENOPAUSAL SYNDROMES
WO2023150072A1 (en) 2022-02-01 2023-08-10 Sinclair David A Compositions and methods for the preservation of plant matter
EP4472993A2 (en) * 2022-02-04 2024-12-11 Elysium Health, Inc. Ribose linkers and conjugates thereof
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022680B2 (en) * 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7927859B2 (en) * 2003-08-22 2011-04-19 Rice University High molar succinate yield bacteria by increasing the intracellular NADH availability
WO2005077091A2 (en) 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
PT1755391E (pt) 2004-06-04 2016-02-03 Univ Washington Métodos e composições para o tratamento de neuropatias
ES2670927T3 (es) * 2005-11-18 2018-06-04 Cornell Research Foundation, Inc. Composiciones de nicotinoil ribósido y métodos de uso
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
KR20210107895A (ko) 2013-10-30 2021-09-01 크로마덱스 아이엔씨. 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물
RU2016149767A (ru) 2014-06-06 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Аналоги никотинамидрибозида и фармацевтические композиции и их применение
BR112017019696A2 (pt) * 2015-03-16 2018-09-04 ChromaDex Inc. composto e usos de um composto
US10392414B2 (en) 2015-07-15 2019-08-27 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
AU2016302005B2 (en) 2015-08-05 2021-03-04 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
ES2981479T3 (es) * 2016-04-14 2024-10-09 Chromadex Inc Fórmula para lactantes que comprende ribósido de nicotinamida

Also Published As

Publication number Publication date
JP7089480B2 (ja) 2022-06-22
BR112018071573A2 (pt) 2019-02-12
AU2022221384B2 (en) 2023-03-23
JP2019514874A (ja) 2019-06-06
AU2022221384C1 (en) 2023-08-03
EP3445359C0 (en) 2023-06-07
NZ747693A (en) 2023-07-28
WO2017184885A1 (en) 2017-10-26
US20170304338A1 (en) 2017-10-26
EP3445359B8 (en) 2023-09-06
MX2018012849A (es) 2019-08-29
US10183036B2 (en) 2019-01-22
EP3445359A4 (en) 2019-12-25
JP2021176871A (ja) 2021-11-11
CN109640984A (zh) 2019-04-16
ZA201807736B (en) 2020-05-27
CA3021571A1 (en) 2017-10-26
KR20190008246A (ko) 2019-01-23
EP3445359B1 (en) 2023-06-07
AU2017254657A1 (en) 2018-11-15
ES2948968T3 (es) 2023-09-22
JP7493007B2 (ja) 2024-05-30
AU2022221384A1 (en) 2022-09-22
JP2023002685A (ja) 2023-01-10
MX393076B (es) 2025-03-24
WO2017184885A8 (en) 2023-08-24
EP3445359A1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
AU2022221384B2 (en) Use of Nicotinic acid Riboside or Nicotinamide Ribosite derivatives, and reduced derivatives thereof, as nad+ increasing precursors
CA3021022C (en) Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula
US10934322B2 (en) B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
AU2020224158B2 (en) Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations
AU2019214858B2 (en) Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CA2696878A1 (en) Compositions and methods for treatment of mitochondrial diseases
HK40004710A (en) Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors
US20230295211A1 (en) Methods of producing crystalline beta nicotinamide riboside triacetate chloride

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201113

EEER Examination request

Effective date: 20201113

EEER Examination request

Effective date: 20201113

EEER Examination request

Effective date: 20201113

EEER Examination request

Effective date: 20201113

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250411

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250411